Acutely damaged axons are remyelinated in multiple sclerosis and experimental models of demyelination
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
Remyelination is in the center of new therapies for the treatment of multiple sclerosis to resolve and improve disease symptoms and protect axons from further damage. Although remyelination is considered beneficial in the long term, it is not known, whether this is also the case early in lesion formation. Additionally, the precise timing of acute axonal damage and remyelination has not been assessed so far. To shed light onto the interrelation between axons and the myelin sheath during de‐ and remyelination, we employed cuprizone‐ and focal lysolecithin‐induced demyelination and performed time course experiments assessing the evolution of early and late stage remyelination and axonal damage. We observed damaged axons with signs of remyelination after cuprizone diet cessation and lysolecithin injection. Similar observations were made in early multiple sclerosis lesions. To assess the correlation of remyelination and axonal damage in multiple sclerosis lesions, we took advantage of a cohort of patients with early and late stage remyelinated lesions and assessed the number of APP‐ and SMI32‐ positive damaged axons and the density of SMI31‐positive and silver impregnated preserved axons. Early de‐ and remyelinating lesions did not differ with respect to axonal density and axonal damage, but we observed a lower axonal density in late stage demyelinated multiple sclerosis lesions than in remyelinated multiple sclerosis lesions. Our findings suggest that remyelination may not only be protective over a long period of time, but may play an important role in the immediate axonal recuperation after a demyelinating insult.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cortical demyelination and diffuse white matter injury in multiple sclerosis
Kutzelnigg, A., Lucchinetti, C. F., Stadelmann, C., Brück, W., Rauschka, H., Bergmann, M., Schmidbauer, M., Parisi, J. E., & Lassmann, H. (2005) · Brain · doi:10.1093/brain/awh641 · Cited by 1,836
Self-citationOligodendroglia metabolically support axons and contribute to neurodegeneration
Lee, Y., Morrison, B. M., Li, Y., Lengacher, S., Farah, M. H., Hoffman, P. N., Liu, Y., Tsingalia, A., Jin, L., Zhang, P.-W., et al. (2012) · Nature · doi:10.1038/nature11314 · Cited by 1,664 · cited 2×
“restores the close metabolic interaction with oligodendrocytes (F€ unfschilling et al., 2012; Lee et al., 2012; Morrison et al., 2015).”
BackgroundGlycolytic oligodendrocytes maintain myelin and long-term axonal integrity
Fünfschilling, U., Supplie, L. M., Mahad, D., Boretius, S., Saab, A. S., Edgar, J., Brinkmann, B. G., Kassmann, C. M., Tzvetanova, I. D., Möbius, W., et al. (2012) · Nature · doi:10.1038/nature11007 · Cited by 1,523
Microglia in the adult brain arise from Ly-6ChiCCR2+ monocytes only under defined host conditions
Mildner, A., Schmidt, H., Nitsche, M., Merkler, D., Hanisch, U.-K., Mack, M., Heikenwalder, M., Brück, W., Priller, J., & Prinz, M. (2007) · Nature Neuroscience · doi:10.1038/nn2015 · Cited by 1,089
Self-citationMatsushima, G. K., & Morell, P. (2001) · Brain Pathology · doi:10.1111/j.1750-3639.2001.tb00385.x · Cited by 984
A reversible form of axon damage in experimental autoimmune encephalomyelitis and multiple sclerosis
Nikić, I., Merkler, D., Sorbara, C., Brinkoetter, M., Kreutzfeldt, M., Bareyre, F. M., Brück, W., Bishop, D., Misgeld, T., & Kerschensteiner, M. (2011) · Nature Medicine · doi:10.1038/nm.2324 · Cited by 713 · cited 4×
“Nikic and colleagues reported that axonal damage is reversible and does not lead to axonal degeneration in all cases (Nikic et al., 2011).”
BackgroundSelf-citationMicroglial/macrophage accumulation during cuprizone-induced demyelination in C57BL/6 mice
Hiremath, M. M., Saito, Y., Knapp, G. W., Ting, J. P.-Y., Suzuki, K., & Matsushima, G. K. (1998) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(98)00168-4 · Cited by 459 · cited 2×
“…level of demyelination of the corpus callosum after cuprizone treatment was assessed in LFB-PAS stained and MBP immunostained sections by a semi-quantitative score: no demyelination (0), 0–33% demyelination (1), 33%–66% demyelination (2), and more than 66% demyelination (3) (Hiremath et al., 1998).”
BackgroundMethodRemyelination protects axons from demyelination-associated axon degeneration
Irvine, K. A., & Blakemore, W. F. (2008) · Brain · doi:10.1093/brain/awn080 · Cited by 420 · cited 2×
“Remyelination thus seemed to be axon-protective, and no evidence for heightened vulnerability of axons during early remyelination was observed in our models (Irvine & Blakemore, 2006, 2008).”
BackgroundSkripuletz, T., Hackstette, D., Bauer, K., Gudi, V., Pul, R., Voss, E., Berger, K., Kipp, M., Baumgärtner, W., & Stangel, M. (2013) · Brain · doi:10.1093/brain/aws262 · Cited by 376
Regional differences between grey and white matter in cuprizone induced demyelination
Gudi, V., Moharregh-Khiabani, D., Skripuletz, T., Koutsoudaki, P. N., Kotsiari, A., Skuljec, J., Trebst, C., & Stangel, M. (2009) · Brain Research · doi:10.1016/j.brainres.2009.06.005 · Cited by 260 · cited 2×
“For most of the studies exploring mechanisms of demyelination, remyelination and axonal damage in the cuprizone mouse model, time intervals of weeks or months were used (Gudi et al., 2009; Lindner, Fokuhl, Linsmeier, Trebst, & Stangel, 2009; Lindner et al., 2008; Skripuletz et al., 2013; Stidworthy, Genoud, Suter, Man…”
MethodPierce, J., Trojanowski, J., Graham, D., Smith, D., & McIntosh, T. (1996) · The Journal of Neuroscience · doi:10.1523/jneurosci.16-03-01083.1996 · Cited by 239
Oligodendrocytes in the early course of multiple sclerosis
Brück, W., Schmied, M., Suchanek, G., Brück, Y., Breitschopf, H., Poser, S., Piddlesden, S., & Lassmann, H. (1994) · Annals of Neurology · doi:10.1002/ana.410350111 · Cited by 216
Self-citationMason, J. L., Toews, A., Hostettler, J. D., Morell, P., Suzuki, K., Goldman, J. E., & Matsushima, G. K. (2004) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63726-1 · Cited by 212
Mechanisms of white matter damage in multiple sclerosis
Lassmann, H. (2014) · Glia · doi:10.1002/glia.22597 · Cited by 191 · cited 1×
“A number of inflammatory mediators have been accused to impair axonal function, mainly derived from phagocytes actively stripping off the myelin sheaths in early lesions (Clark et al., 2016; Cunningham, 2013; Lassmann, 2014).”
BackgroundSingh, S., Dallenga, T., Winkler, A., Roemer, S., Maruschak, B., Siebert, H., Brück, W., & Stadelmann, C. (2017) · Journal of Neuroinflammation · doi:10.1186/s12974-017-0831-8 · Cited by 118 · cited 1×
“Persistent disability and disease progression in multiple sclerosis are tightly connected to neuro-axonal damage and loss (Simons, Misgeld, & Kerschensteiner, 2014; Singh et al., 2017).”
BackgroundSelf-citationLate motor decline after accomplished remyelination: Impact for progressive multiple sclerosis
Manrique‐Hoyos, N., Jürgens, T., Grønborg, M., Kreutzfeldt, M., Schedensack, M., Kuhlmann, T., Schrick, C., Brück, W., Urlaub, H., Simons, M., et al. (2012) · Annals of Neurology · doi:10.1002/ana.22681 · Cited by 107
Self-citationMHC class II exacerbates demyelination in vivo independently of T cells
Hiremath, M. M., Chen, V. S., Suzuki, K., Ting, J. P.-Y., & Matsushima, G. K. (2008) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2008.06.034 · Cited by 77
Cited by
Myelin in the Central Nervous System: Structure, Function, and Pathology
Stadelmann, C., Timmler, S., Barrantes-Freer, A., & Simons, M. (2019) · Physiological Reviews · doi:10.1152/physrev.00031.2018 · Cited by 728
Self-citationThe impact of the gut microbiome on extra-intestinal autoimmune diseases
Miyauchi, E., Shimokawa, C., Steimle, A., Desai, M. S., & Ohno, H. (2023) · Nature Reviews Immunology · doi:10.1038/s41577-022-00727-y · Cited by 367
Remyelination in multiple sclerosis: From basic science to clinical translation
Lubetzki, C., Zalc, B., Williams, A., Stadelmann, C., & Stankoff, B. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30140-x · Cited by 350
Self-citationThe adult oligodendrocyte can participate in remyelination
Duncan, I. D., Radcliff, A. B., Heidari, M., Kidd, G., August, B. K., & Wierenga, L. A. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1808064115 · Cited by 259
Mechanisms of lysophosphatidylcholine‐induced demyelination: A primary lipid disrupting myelinopathy
Plemel, J. R., Michaels, N. J., Weishaupt, N., Caprariello, A. V., Keough, M. B., Rogers, J. A., Yukseloglu, A., Lim, J., Patel, V. V., Rawji, K. S., et al. (2018) · Glia · doi:10.1002/glia.23245 · Cited by 220
Metadata
- Authors
- Schultz, V., van der Meer, F., Wrzos, C., Scheidt, U., Bahn, E., Stadelmann, C., Brück, W., & Junker, A.
- Venue
- Glia
- Publisher
- Wiley
- Published
- 2017-05-31
- Volume
- 65
- Issue
- 8
- Pages
- 1350-1360
- ISSN
- 0894-1491 (ISSN-L)
- 1098-1136
- OpenAlex
- W2616963432
- Cited by
- 71
- References
- 17
- FWCI
- 7.23
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.